UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer

Clinical cancer research, 2017-07, Vol.23 (14), p.3585-3591

2017

Volltextzugriff (PDF)

Impact of Decalcification, Cold Ischemia, and Deglycosylation on Performance of Programmed Cell Death Ligand-1 Antibodies With Different Binding Epitopes: Comparison of 7 Clones

Modern pathology, 2023-09, Vol.36 (9), p.100220-100220, Article 100220

2023

Volltextzugriff (PDF)

Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay

Diagnostic pathology, 2018-07, Vol.13 (1), p.47-47, Article 47

2018

Volltextzugriff (PDF)

Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma

Diagnostic pathology, 2019-09, Vol.14 (1), p.99-99, Article 99

2019

Volltextzugriff (PDF)

Panel based MALDI-TOF tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour

PloS one, 2014-06, Vol.9 (6), p.e100566-e100566

2014

Volltextzugriff (PDF)

CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans

The Journal of clinical investigation, 2009-09, Vol.119 (9), p.2564-2576

2009

Volltextzugriff (PDF)

Nuclear localization is required for Dishevelled function in Wnt/beta-catenin signaling

Journal of biology (London, England), 2005, Vol.4 (1), p.3-3

2005

Volltextzugriff (PDF)

Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARδ agonists

Bioorganic & medicinal chemistry letters, 2011-01, Vol.21 (1), p.492-496

2011

Volltextzugriff (PDF)

Prostaglandin D2 regulates CD4+ memory T cell trafficking across blood vascular endothelium and primes these cells for clearance across lymphatic endothelium

The Journal of immunology (1950), 2011-08, Vol.187 (3), p.1432-1439

2011

Volltextzugriff (PDF)

Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer

Oncotarget, 2017-02, Vol.8 (7), p.12501-12516

2017

Volltextzugriff (PDF)

ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study

Journal of thoracic oncology, 2016-10, Vol.11 (10), p.1682-1689

2016

Volltextzugriff (PDF)

Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review

Journal of experimental & clinical cancer research, 2015-09, Vol.34 (1), p.92-92, Article 92

2015

Volltextzugriff (PDF)

EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study

Lung cancer (Amsterdam, Netherlands), 2017-11, Vol.113, p.37-44

2017

Volltextzugriff (PDF)

Cytology for PD-L1 testing: A systematic review

Lung cancer (Amsterdam, Netherlands), 2020-03, Vol.141, p.101-106

2020

Volltextzugriff (PDF)

A Positive Role for the PP2A Catalytic Subunit in Wnt Signal Transduction

The Journal of biological chemistry, 2000-11, Vol.275 (46), p.35680-35683

2000

Volltextzugriff (PDF)

Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study

Journal of thoracic oncology, 2019-08, Vol.14 (8), p.1390-1399

2019

Volltextzugriff (PDF)

EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic Survey

Journal of thoracic oncology, 2015-03, Vol.10 (3), p.438-445

2015

Volltextzugriff (PDF)

Assessment of heterogeneity of PD-L1 expression in NSCLC, HNSCC, and UC with Ventana SP263 assay

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e14502-e14502

2017

Volltextzugriff (PDF)

Abstract LB-094: A comparative study of PD-L1 diagnostic assays and the classification of patients as PD-L1 positive and PD-L1 negative

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.LB-094-LB-094

2016

Volltextzugriff (PDF)

Identifying functionally important aberrations of Neurofibromin-1 (NF1) in non-small cell lung cancer (NSCLC)

European journal of surgical oncology, 2018-03, Vol.44, p.S36-S36

2018

Volltextzugriff (PDF)

Concordance of tumor cell (TC) and immune cell (IC) staining with Ventana SP142, Ventana SP263, Dako 28-8 and Dako 22C3 PD-L1 IHC tests in NSCLC patient samples

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e14503-e14503

2017

Volltextzugriff (PDF)

Abstract 5530: PD-L1 expression in patients screened for phase 2 head and neck squamous cell carcinoma clinical studies (HAWK and CONDOR)

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.5530-5530

2018

Volltextzugriff (PDF)

Identifying functionally important aberrations of Neurofibromin-1 (NF1) in non-small cell lung cancer (NSCLC)

European journal of surgical oncology, 2017-11, Vol.43 (11), p.2233-2233

2017

Volltextzugriff (PDF)

Concordance of tumor and immune cell staining with Ventana SP142, Ventana SP263, Dako 28-8 and Dako 22C3 PD-L1 tests in NSCLC patient samples

Journal of clinical oncology, 2017-03, Vol.35 (7_suppl), p.7-7

2017

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(50)
Dissertationen
(1)

Sprache

Englisch
(49)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(27)
Humans
(24)
Life Sciences & Biomedicine
(24)
Male
(10)
Female
(9)
Middle Aged
(8)
Oncology
(8)
Aged
(7)
Animals
(7)
Carcinoma, Non-Small-Cell Lung - Genetics
(7)
Immunohistochemistry
(6)
Lung Neoplasms - Genetics
(6)
Biochemistry & Molecular Biology
(5)
Mutation
(5)
Pathology
(5)
Respiratory System
(5)
Biomarkers
(4)
Carcinoma, Non-Small-Cell Lung - Pathology
(4)
Cells, Cultured
(4)
Cerebrospinal Fluid
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer

Impact of Decalcification, Cold Ischemia, and Deglycosylation on Performance of Programmed Cell Death Ligand-1 Antibodies With Different Binding Epitopes: Comparison of 7 Clones

Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay

Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma

Panel based MALDI-TOF tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour

"Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy

CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans

Nuclear localization is required for Dishevelled function in Wnt/beta-catenin signaling

Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARδ agonists

Prostaglandin D2 regulates CD4+ memory T cell trafficking across blood vascular endothelium and primes these cells for clearance across lymphatic endothelium

Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer

ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study

Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review

EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study

Cytology for PD-L1 testing: A systematic review

A Positive Role for the PP2A Catalytic Subunit in Wnt Signal Transduction

Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study

EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic Survey

Assessment of heterogeneity of PD-L1 expression in NSCLC, HNSCC, and UC with Ventana SP263 assay

Abstract LB-094: A comparative study of PD-L1 diagnostic assays and the classification of patients as PD-L1 positive and PD-L1 negative

Identifying functionally important aberrations of Neurofibromin-1 (NF1) in non-small cell lung cancer (NSCLC)

Concordance of tumor cell (TC) and immune cell (IC) staining with Ventana SP142, Ventana SP263, Dako 28-8 and Dako 22C3 PD-L1 IHC tests in NSCLC patient samples

Abstract 5530: PD-L1 expression in patients screened for phase 2 head and neck squamous cell carcinoma clinical studies (HAWK and CONDOR)

Identifying functionally important aberrations of Neurofibromin-1 (NF1) in non-small cell lung cancer (NSCLC)

Concordance of tumor and immune cell staining with Ventana SP142, Ventana SP263, Dako 28-8 and Dako 22C3 PD-L1 tests in NSCLC patient samples

Suchergebnisse filtern